RESEARCH STUDY

ONTRAC: oral nicotinamide for skin-cancer prevention (RCT, 2015)

2015
RCT
386
High

One-line finding

Oral nicotinamide 500 mg twice daily cut new non-melanoma skin cancers by about 23% versus placebo.

Plain-language summary

This was a large, well-run trial in people who had already had several skin cancers. Taking nicotinamide by mouth for a year lowered the rate of new non-melanoma skin cancers and precancerous spots (actinic keratoses). Note: this is about the oral supplement, not topical skincare, and applies to high-risk patients, not the general public.

Citation

Read the study